765 related articles for article (PubMed ID: 33189127)
21. Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for gastroenteropancreatic neuroendocrine neoplasm.
Er LM; Wu ML; Gao Y; Wang SJ; Li Y
J Clin Lab Anal; 2017 Sep; 31(5):. PubMed ID: 27704598
[TBL] [Abstract][Full Text] [Related]
22. Peritoneal Metastases from Gastroenteropancreatic Neuroendocrine Tumors: Incidence, Risk Factors and Prognosis.
Madani A; Thomassen I; van Gestel YRBM; van der Bilt JDW; Haak HR; de Hingh IHJT; Lemmens VEPP
Ann Surg Oncol; 2017 Aug; 24(8):2199-2205. PubMed ID: 28204963
[TBL] [Abstract][Full Text] [Related]
23. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
24. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias.
Albers MB; Almquist M; Bergenfelz A; Nordenström E
Langenbecks Arch Surg; 2020 Mar; 405(2):137-143. PubMed ID: 32291468
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database.
Panzuto F; Partelli S; Campana D; de Braud F; Spada F; Cives M; Tafuto S; Bertuzzi A; Gelsomino F; Bergamo F; Marcucci S; Mastrangelo L; Massironi S; Appetecchia M; Filice A; Badalamenti G; Bartolomei M; Amoroso V; Landoni L; Rodriquenz MG; Valente M; Colao A; Isidori A; Fanciulli G; Bollina R; Ciola M; Butturini G; Marconcini R; Arvat E; Cinieri S; Berardi R; Baldari S; Riccardi F; Spoto C; Giuffrida D; Gattuso D; Ferone D; Rinzivillo M; Bertani E; Versari A; Zerbi A; Lamberti G; Lauricella E; Pusceddu S; Fazio N; Dell'Unto E; Marini M; Falconi M
Endocrine; 2024 Apr; 84(1):42-47. PubMed ID: 38175391
[TBL] [Abstract][Full Text] [Related]
26. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
27. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.
Faggiano A; Ferolla P; Grimaldi F; Campana D; Manzoni M; Davì MV; Bianchi A; Valcavi R; Papini E; Giuffrida D; Ferone D; Fanciulli G; Arnaldi G; Franchi GM; Francia G; Fasola G; Crinò L; Pontecorvi A; Tomassetti P; Colao A
J Endocrinol Invest; 2012 Oct; 35(9):817-23. PubMed ID: 22080849
[TBL] [Abstract][Full Text] [Related]
28. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
29. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
30. Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.
Zhang XB; Fan YB; Jing R; Getu MA; Chen WY; Zhang W; Dong HX; Dakal TC; Hayat A; Cai HJ; Ashrafizadeh M; Abd El-Aty AM; Hacimuftuoglu A; Liu P; Li TF; Sethi G; Ahn KS; Ertas YN; Chen MJ; Ji JS; Ma L; Gong P
Mil Med Res; 2024 Jun; 11(1):35. PubMed ID: 38835066
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients.
Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ
World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833
[TBL] [Abstract][Full Text] [Related]
32. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).
Puccini A; Poorman K; Salem ME; Soldato D; Seeber A; Goldberg RM; Shields AF; Xiu J; Battaglin F; Berger MD; Tokunaga R; Naseem M; Barzi A; Iqbal S; Zhang W; Soni S; Hwang JJ; Philip PA; Sciallero S; Korn WM; Marshall JL; Lenz HJ
Clin Cancer Res; 2020 Nov; 26(22):5943-5951. PubMed ID: 32883742
[TBL] [Abstract][Full Text] [Related]
34. The real-world selection of first-line systemic therapy regimen for metastatic gastroenteropancreatic neuroendocrine neoplasm in Japan.
Yamamoto S; Sakakibara N; Hirano H; Morizane C; Honma Y; Hijioka S; Okusaka T; Higashi T; Kawai A
Sci Rep; 2022 Oct; 12(1):17601. PubMed ID: 36266484
[TBL] [Abstract][Full Text] [Related]
35. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
[TBL] [Abstract][Full Text] [Related]
36. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.
Gao C; Fan Z; Yang J; Shi M; Li Y; Zhan H
Pancreatology; 2023 Mar; 23(2):204-212. PubMed ID: 36710224
[TBL] [Abstract][Full Text] [Related]
38. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
39. Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma.
Ooki A; Osumi H; Fukuda K; Yamaguchi K
Cancer Metastasis Rev; 2023 Sep; 42(3):1021-1054. PubMed ID: 37422534
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
